MX9305887A - Uso de acido hialuronico y formas para evitar restenosis arterial. - Google Patents
Uso de acido hialuronico y formas para evitar restenosis arterial.Info
- Publication number
- MX9305887A MX9305887A MX9305887A MX9305887A MX9305887A MX 9305887 A MX9305887 A MX 9305887A MX 9305887 A MX9305887 A MX 9305887A MX 9305887 A MX9305887 A MX 9305887A MX 9305887 A MX9305887 A MX 9305887A
- Authority
- MX
- Mexico
- Prior art keywords
- hyaluronic acid
- ways
- arterial restenosis
- avoid
- avoid arterial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
Para evitar el angostamiento de paredes tubulares de un animal después de que las paredes tubulares han tenido un traumatismo, la administración de una cantidad no tóxica, perapéuticamente efectiva de ácido hialurónico y/o sales del mismo y/u homólogos, análogos, derivados, complejos, ésteres, fragmentos y subunidades del ácido hialurónico al animal, para evitar el angostamiento de las paredes tubulares.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002079205A CA2079205C (en) | 1992-09-25 | 1992-09-25 | Use of hyaluronic acid and forms to prevent arterial restenosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9305887A true MX9305887A (es) | 1994-05-31 |
Family
ID=4150463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9305887A MX9305887A (es) | 1992-09-25 | 1993-09-24 | Uso de acido hialuronico y formas para evitar restenosis arterial. |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP0661981B1 (es) |
JP (1) | JP3742955B2 (es) |
CN (1) | CN1057908C (es) |
AP (1) | AP448A (es) |
AT (1) | ATE141054T1 (es) |
AU (1) | AU670117B2 (es) |
BR (1) | BR9307221A (es) |
CA (1) | CA2079205C (es) |
CZ (1) | CZ288986B6 (es) |
DE (1) | DE69303931T2 (es) |
DK (1) | DK0661981T3 (es) |
ES (1) | ES2091031T3 (es) |
GR (1) | GR3021171T3 (es) |
HK (1) | HK35397A (es) |
HU (2) | HU227067B1 (es) |
IL (1) | IL107087A0 (es) |
IN (1) | IN181289B (es) |
MD (1) | MD960294A (es) |
MX (1) | MX9305887A (es) |
NO (1) | NO309457B1 (es) |
NZ (1) | NZ255978A (es) |
PL (1) | PL308201A1 (es) |
SG (1) | SG48845A1 (es) |
SK (1) | SK36895A3 (es) |
TW (1) | TW271401B (es) |
ZA (1) | ZA937068B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6663881B2 (en) | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
WO1999010385A1 (fr) * | 1997-08-22 | 1999-03-04 | Denki Kagaku Kogyo Kabushiki Kaisha | Gel d'acide hyaluronique, son procede de production et substance therapeutique le contenant |
FR2813791B1 (fr) | 2000-09-14 | 2004-03-12 | Lafon Labor | Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale |
FR2994846B1 (fr) | 2012-08-29 | 2014-12-26 | Vivacy Lab | Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
-
1992
- 1992-09-25 CA CA002079205A patent/CA2079205C/en not_active Expired - Lifetime
-
1993
- 1993-09-22 TW TW082107796A patent/TW271401B/zh active
- 1993-09-22 NZ NZ255978A patent/NZ255978A/en not_active IP Right Cessation
- 1993-09-22 MD MD96-0294A patent/MD960294A/ro not_active Application Discontinuation
- 1993-09-22 AU AU48126/93A patent/AU670117B2/en not_active Expired
- 1993-09-22 BR BR9307221A patent/BR9307221A/pt not_active Application Discontinuation
- 1993-09-22 CZ CZ1995662A patent/CZ288986B6/cs not_active IP Right Cessation
- 1993-09-22 AT AT93920624T patent/ATE141054T1/de active
- 1993-09-22 PL PL93308201A patent/PL308201A1/xx unknown
- 1993-09-22 SK SK368-95A patent/SK36895A3/sk unknown
- 1993-09-22 AP APAP/P/1993/000568A patent/AP448A/en active
- 1993-09-22 SG SG1996002824A patent/SG48845A1/en unknown
- 1993-09-22 EP EP93920624A patent/EP0661981B1/en not_active Expired - Lifetime
- 1993-09-22 JP JP50854394A patent/JP3742955B2/ja not_active Expired - Lifetime
- 1993-09-22 HU HU9500857A patent/HU227067B1/hu unknown
- 1993-09-22 ES ES93920624T patent/ES2091031T3/es not_active Expired - Lifetime
- 1993-09-22 DE DE69303931T patent/DE69303931T2/de not_active Expired - Lifetime
- 1993-09-22 DK DK93920624.9T patent/DK0661981T3/da active
- 1993-09-23 IL IL107087A patent/IL107087A0/xx not_active IP Right Cessation
- 1993-09-24 CN CN93119844A patent/CN1057908C/zh not_active Expired - Fee Related
- 1993-09-24 ZA ZA937068A patent/ZA937068B/xx unknown
- 1993-09-24 MX MX9305887A patent/MX9305887A/es unknown
-
1995
- 1995-03-23 NO NO951122A patent/NO309457B1/no not_active IP Right Cessation
- 1995-06-13 IN IN670CA1995 patent/IN181289B/en unknown
- 1995-06-30 HU HU95P/P00651P patent/HU211698A9/hu unknown
-
1996
- 1996-09-26 GR GR960402522T patent/GR3021171T3/el unknown
-
1997
- 1997-03-20 HK HK35397A patent/HK35397A/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2082288T3 (es) | Composiciones terapeuticas para administracion intranasal de ketorolaco. | |
BR9406979A (pt) | Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal | |
ES2059965T3 (es) | Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias. | |
MX9300904A (es) | Composiciones que contienen acido hialuronico | |
ES2054995T3 (es) | Nuevos derivados del acido benzoico y acido fenilacetico, su obtencion y empleo como medicamentos. | |
ES2190674T3 (es) | Uso de n-alquil derivados de cadena larga de desoxinojirimicina para la fabricacion de un medicamento para el tratamiento de enfermedades de acumulacion de glucolipidos. | |
ES2139132T3 (es) | Composiciones farmaceuticas activas en la terapia de desordenes del sueño. | |
ES2164920T3 (es) | Nuevos derivados heterociclicos y uso medicinal de los mismos. | |
ES2054860T5 (es) | Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos. | |
MX9305769A (es) | Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
ES2160693T3 (es) | Formulacion estable de 10-hidroxi-7-etil-camptotecina en la forma lactona. | |
ES2192234T3 (es) | Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos. | |
NL980018I1 (nl) | Antivirale combinaties die nucleoside-analoga bevatten. | |
ES2143132T3 (es) | Monohidratos de derivado de acido aminobenceno-sulfonico y su metodo de preparacion. | |
MX9300905A (es) | Tratamiento de enfermedad que emplea acido hialuronico y agentes anti-inflamatorios no esteroidales | |
ES2157422T3 (es) | Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos. | |
ES2176468T3 (es) | Uso de acido hialuronico y un nsaid para la fabricacion de un medicamento para el tratamiento de enfermedades de las mucosas. | |
AR012504A1 (es) | Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion. | |
MX9305887A (es) | Uso de acido hialuronico y formas para evitar restenosis arterial. | |
ES2041705T3 (es) | Procedimiento para la preparacion de 1-(4-hidroxi-3,5-di-terc-butil-benzoil)-homopiperazina y sus derivados. | |
AR012946A1 (es) | Forma cristalina a de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida, preparaciones farmaceuticas que los contienen y su uso para la preparacion de medicamentos | |
IT8025159A0 (it) | Preparato medicinale ad azione citostatica, nonche' derivati dell'acido isocianurico eprocedimento per la loro preparazione. | |
AR001769A1 (es) | Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación | |
ES2125356T3 (es) | Empleo de leflunomida para la inhibicion de interleuquina 8. | |
ES2178718T3 (es) | Nuevos derivados de pirazoles acidos, su procedimiento de preparaacion, su aplicacion como medicamentos, su nueva utilizacion y composicion farmaceuticas que los contienen. |